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Abstract     
Dysregulation of microRNAs (miRNAs) plays an important role in the pathogenesis of chronic 
lymphocytic leukemia (CLL). The Eμ-TCL1 transgenic mouse develops a form of leukemia that is 
similar to the aggressive type of human B-CLL, and this valuable model has been widely used for 
testing novel therapeutic approaches. Here, we adopted this model to investigate the potential 
effects of miR-26a, miR-130an and antimiR-155 in CLL therapy. 
Improved delivery of miRNA molecules into CLL cells was obtained by developing a novel system 
based on lipid nanoparticles conjugated with an anti-CD38 monoclonal antibody. This 
methodology has proven to be highly effective in delivering miRNA molecules into leukemic cells. 
Short and long-term experiments showed that miR-26a, miR-130a and anti-miR-155 increased  
apoptosis after in vitro and in vivo treatment. Of this miRNA panel, miR-26a was the most effective 
in reducing leukemic cell expansion. Following long-term treatment, apoptosis was readily 
detectable by analyzing cleavage of PARP and caspase-7. These effects could be directly attributed 
to miR-26a, as confirmed by significant downregulation of its proven targets, namely cyclin-
dependent kinase 6 and Mcl1. 
The results of this study are relevant to two distinct areas. The first is related to the design of a 
technical strategy and to the selection of CD38 as a molecular target on CLL cells, both consenting 
efficient and specific intracellular transfer of miRNA. The original scientific finding inferred from 
the above approach is that miR-26a can elicit in vivo anti-leukemic activities mediated by 
increased apoptosis.  
 
 
Keywords: miRNA, CLL, Nanoparticles, CD38, miRNA delivery. 
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Introduction 1 
Chronic lymphocytic leukemia (CLL) is the most common B-cell malignancy in Western countries. 2 
CLL lymphocytes resemble memory B cells with a mature phenotype (1). This leukemia is 3 
characterized by the accumulation of CD5+ B lymphocytes in the blood, spleen, liver, lymph nodes, 4 
and bone marrow. Despite its morphological homogeneity, CLL is a clinically heterogeneous 5 
disease (2-4) with a number of adverse factors that affect the clinical course, including stage(5); 6 
CD38 positivity; unmutated variable region of the immunoglobulin heavy chain gene (IGHV) (6); 7 
ZAP70 positivity (7); karyotype aberrations (8); and TP53, NOTCH1, SF3B1, and other gene 8 
mutations (9, 10). Despite the progress in chemoimmunotherapy, CLL remains an incurable 9 
disease (11). 10 
To help decipher the pathogenic mechanisms of disease and evaluate the efficacy and 11 
mechanisms of action of novel therapies, researchers have developed mouse models that 12 
resemble human CLL (12, 13). The Eµ-TCL1 transgenic (TCL1-tg) mouse develops a leukemia that is 13 
highly similar to the aggressive form of human CLL (14-16). An important feature of TCL1 14 
overexpression is that it exhibits 100% disease penetrance. At the age of 16–20 months, these 15 
mice show a B-CLL-like disease characterized by spleno- and hepatomegaly associated with high 16 
counts of white blood cells. Leukemias are characterized by clonal expansion of B cells with a 17 
B220+/IgM+/CD5+ immunophenotype, unmutated IGHV, increased proliferation, and enhanced 18 
AKT phosphorylation. Tumor cells in TCL1-tg mice have wild-type (WT) p53 and initially respond to 19 
fludarabine treatment (17). Notably, leukemic cells from a TCL1-tg donor can be transplanted by 20 
intraperitoneal (IP) or intravenous injection into syngeneic WT or immunodeficient mice (e.g., 21 
SCID) to accelerate the disease course and generate genetically homogeneous populations of 22 
leukemic cells, which better allows for systematic comparison of novel therapies.  23 
MicroRNAs (miRNAs) play a central role in the pathogenesis of CLL. They regulate gene expression 24 
at the post-transcriptional level by targeting messenger RNA for degradation or translational 25 
inhibition and thus can modulate several biological processes. As a consequence of their 26 
deregulation, miRNAs may act as oncogenes or tumor suppressors (18). The discovery of the 27 
involvement of miRNAs in human cancer originated from studies of CLL (19). miR-15a and miR-16-28 
1 were found within the minimal region of deletion at chromosome 13q, the most frequent 29 
genetic alteration found in human CLL. Deletion of miR-15a/miR-16-1 in a knockout mouse model 30 
was shown to confer predisposition to the development of an indolent form of leukemia similar to 31 
human CLL (20). BCL2 was a target of these miRNAs; thus, their loss eliminated control over BCL2 32 
expression (21). It is notable that venetoclax, a highly active and recently approved drug against 33 
CLL, was designed to inhibit BCL2 activity (22). A prognostic signature consisting of a panel of 34 
aberrantly expressed miRNAs has been identified in CLL (23). Other important miRNAs in human 35 
CLL include miR-34a, which, being an effector of the p53 protein, is strongly downregulated in 36 
17p-CLL cases, or miR-181b, which is downregulated during disease progression (24-26). In a more 37 
recent comprehensive study, we found that a number of miRNAs are deregulated in CLL (27). 38 
miRNAs were differentially expressed between CLL cells and mature antigen-experienced B cells, 39 
or correlated to specific pathological features (IGHV somatic mutations or specific cytogenetic 40 
aberrations) or clinical parameters, such as time to first treatment (27). These studies established 41 
the groundwork from which miRNA-based therapies, either by restoring or repressing miRNA 42 
activity, could be designed and tested. We have already investigated miR-181b as a potential 43 
therapeutic molecule against leukemias of the TCL1-tg mouse model (28).  The study proved that 44 
this miRNA induced a measurable anti-leukemic effect. However, an improvement in delivery 45 
methods was suggested.   46 
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Here, we used the Eµ-TCL1FL mouse model (15) to test the anti-leukemic activity of various miRNA 1 
mimics or anti-miRNA oligonucleotides (AMOs). To increase in vivo delivery, we developed a 2 
lipopolyplex formulation that included anti-CD38 conjugated lipid nanoparticles (CD38-NPs), which 3 
considerably increased the specificity for hCD38+ leukemic cells of this mouse model. The choice 4 
of CD38 as a molecule to target CLL cells was guided by its known importance in CLL (29), as well 5 
as its structural characteristics (30)  and the evidence of its antibody-mediated internalization (31).  6 
 7 
Results  8 
Leukemic cells of the Eμ-TCL1FL transgenic mouse are CD38+. Leukemic cells of the Eμ-TCL1FL 9 
transgenic mouse or transplanted into syngeneic FVB mice are characterized by B220+/CD5dim 10 
surface markers (28). Here, we evaluated the expression of CD38. To this end, the splenic 11 
lymphocyte population from transgenic or transplanted FVB mice with a high level of disease was 12 
first sorted on the basis of physical parameters, and the B220+/CD5dim leukemic population was 13 
identified; finally, the lymphocytes within the B220+/CD5dim gate were analyzed for CD38 14 
expression, showing that more than 98% of the cells were positive (Figure 1). This analysis not only 15 
confirmed that the TCL1-tg model exhibits an immunophenotype typical of an aggressive form of 16 
B-CLL characterized by high expression of CD38, but it also provided a way to specifically target 17 
leukemic cells. 18 
Lipid nanoparticles conjugated with anti-CD38 antibodies can efficiently deliver miRNAs into CLL 19 
cells. On the basis of this evidence, we developed lipid nanoparticles conjugated with anti-CD38 20 
antibodies (CD38-NPs) to improve the efficiency of in vivo miRNA delivery into leukemic cells. The 21 
lipid NP-miRNAs were synthesized as described (32).  22 
We investigated the efficiency of CD38-NPs both in vitro and in vivo. In vitro, we tested whether 23 
CD38-NPs could deliver mature miRNAs into murine TCL1-tg leukemic cells. We transfected cells 24 
with miR-181b mimics, miRNA that we had previously investigated (28). Twenty-four hours after 25 
transfection, cells were collected for RNA extraction and the levels of miR-181b measured 26 
(Supplementary Figure 1). These in vitro results indicated that CD38-NPs could efficiently deliver 27 
small RNA into leukemic cells and were approximately 2-fold more efficient than unconjugated 28 
NPs. 29 
The TCL1-tg mouse represented an excellent model for testing in vivo delivery efficiency. We 30 
quantitatively investigated the delivery of 100 μg of miR-181b in different organs of FVB-TCL1 31 
transplanted mice. Mice were treated when they exhibited a lymphocyte disease burden of 30-32 
50% as the percentage of leukemic cells in peripheral blood. We tested CD38-NPs, non-conjugated 33 
NPs, or Jet-PEI, a formulation used in our previous study (28), in 4 mice for each condition. The 34 
nanoparticles were administered by IP injection. After 24 hours, mice were sacrificed and organs 35 
collected. Total RNA was isolated from liver, splenocytes, heart, kidneys, thyroid, lungs, muscle, 36 
stomach, intestine, brain, and bladder and the expression levels of miR-181b were quantified by 37 
digital PCR (Figure 2A). Spleen was the most efficiently targeted organ by CD38-NPs, followed by 38 
liver. Compared with the physiological levels in these organs, the amount of miR-181b increased 39 
more than 300-fold following CD38-NP-mediated delivery. In splenocytes, CD38-NPs induced an 40 
18-fold increase compared with Jet-PEI and a 3-fold increase compared with non-conjugated NPs 41 
(Figure 2B). All other organs exhibited increased expression levels of miR-181b, generally at lower 42 
levels and independent to the type of NP.  43 
The greater delivery mediated by CD38-NPs in spleen and liver of diseased animals was likely 44 
attributable to the presence of a high number of CD38+ cells.  This conclusion was supported by 45 
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the finding that no significant difference of miR-181b in spleen and liver was observed between 1 
CD38-NPs and non-conjugated NPs delivery efficacy when experiment was performed in FVB WT 2 
mice (Supplementary Figure 2). These findings indicated that CD38-NPs were capable of 3 
improving efficiency of delivery and specificity of targeting for CD38+ CLL cells. 4 
miR-26a, miR-130a, and anti-miR-155 are selected as potential anti-leukemic molecules. After 5 
the delivery efficacy of CD38-NPs was verified in vivo and in vitro, we tested the potential anti-6 
leukemic effects of a group of selected miRNAs/anti-miRNAs.  7 
From the results of our previous microRNAome study in human CLL (27), we selected a group of 8 
miRNAs that were deregulated in human CLL. Herein, we tested miRNA mimics miR-15, miR-16, 9 
miR-26a, miR-125a, miR-130a, and miR-34a or AMOs of miR-21, miR-155, and miR-130a. A 10 
scrambled RNA oligo was used as a negative control. 11 
First, we investigated the in vitro biological activity on leukemic splenocytes isolated from the 12 
spleen of Eμ-TCL1FL transgenic mice. Leukemic splenocytes were transfected by the use of CD38-13 
NPs and 48 hours after transfection, apoptotic activity was assessed by Annexin V assay (Figure 14 
3A, supplementary figure 3). The highest apoptotic activity was detected in splenocytes treated 15 
with miR-26a, miR-125a, anti-miR-155 and miR-130a (p < 0.05). The efficiency of transfection of 16 
mimics/AMOs was assessed and confirmed in all the samples by analyzing the expression levels of 17 
each miRNA (Figure 3B).   18 
Next, for in vivo studies, we first evaluated if the CD38-NPs could also mediate a more effective 19 
functional outcome than non-conjugated NPs. Given the high pro-apoptotic activity demonstrated 20 
in vitro, we selected the miR-26a for measuring in vivo biological effects.  100 µg of miR-26a 21 
mimics was delivered into mice with a high disease burden (30-50% TCL1+ cells in peripheral 22 
blood) by using either CD38-NPs or non-conjugated NPs (3 mice in each group). As control, 3 mice 23 
with a similar disease burden were treated with a scrambled RNA oligo. After 48 hours from 24 
treatment (IP injection), mice were sacrificed and splenocytes isolated to analyze the biological 25 
effects. As shown in Figure 4 , in comparison with non-conjugated NPs, the use of CD38-NPs 26 
induced a more effective down-regulation CDK6, a target of miR26a, and a clearer activation of 27 
apoptosis, detectable by cleavage of PARP. 28 
Based on these results, we evaluated a number of miRNA mimics/AMOs for their in vivo biological 29 
activity using CD38-NPs as delivery vehicles. Transplanted mice with a high disease burden (30-30 
50% TCL1+ cells in peripheral blood) were treated with 100 µg of different miRNA mimics or AMOs 31 
(at least 3 mice in each group) by using  CD38-NPs; as control, 4 mice with a similar disease burden 32 
were treated with scrambled miRNA. After 48 hours of a single treatment (IP injection), mice were 33 
sacrificed and splenocytes isolated to analyze the effects of miRNAs on apoptosis by the Annexin V 34 
assay. As shown in Figure 5A, treatment with miR-26a or miR-130a mimics or with anti-miR-155 35 
oligonucleotides induced a significant increase in apoptotic cells compared with control (p < 0.05), 36 
while several other miRNAs did not exhibit significant differences. Notably, CD38-NP-Empty 37 
treated mice exhibited a negligible effect in comparison with control (p = 0.6). The efficiency of 38 
delivery of mimic/AMOs in splenocytes was confirmed by quantitative PCR in all samples (Figure 39 
5B). These results revealed the potential pro-apoptotic activity of miR-26a, miR-130a, and anti-40 
miR-155 against leukemic cells.  41 
miR-26a reduces the expansion of leukemic cells of Eμ-TCL1 mice. Given the observed pro-42 
apoptotic effects after short-term treatments in vitro and in vivo, we sought to assess the 43 
potential anti-leukemic activity of miR-26a, miR-130a, or anti-miR-155 after 3 weeks of treatment. 44 
We performed the experiments by using FVB WT mice transplanted with Eμ-TCL1FL leukemic cells 45 
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as we have previously described (28). Syngeneic transplantations were performed in 6-week-old 1 
mice by IP injection of 5x105 splenocytes, collected from an Eμ-TCL1FL transgenic mouse with 2 
advanced disease. We monitored the progression of leukemia in transplanted syngeneic mice over 3 
time by quantitatively measuring the increase of the human TCL1 transgene, using a biomarker of 4 
transplanted leukemic cells, in DNA isolated from peripheral blood with digital PCR.  5 
Mice were enrolled for treatment at about 8 weeks after transplantation, when leukemic cells 6 
reached 15-30% of peripheral blood lymphocytes. At this stage, mice were assigned to 5 groups of 7 
treatment with the same schedule of administration (IP injection of 100 µg of miRNA mimics or 8 
AMOs 3 times a week for 3 weeks): (1) miR-26a, (2) miR-130a, (3) anti-miR-155, (4) scrambled 9 
oligo control, and (5) CD38-NP-Empty nanoparticles. At the beginning of treatment, each group of 10 
mice exhibited the same or a very similar arithmetic mean and standard deviation of leukemic 11 
burden. 12 
Before starting the treatments and 48 hours after the last treatment, we measured by digital PCR 13 
and FACS analysis the percentage of B220+/CD5+ leukemic cells present in the blood. Results of 14 
the two assays were in agreement. The differences between percentages of leukemic cells before 15 
and after treatment are shown in Figure 6.  miR-26a treatment was the most effective in reducing 16 
the accumulation/expansion of leukemic cells in blood. The other molecules also induced a 17 
reduction of the leukemic cell burden in blood, albeit to a significantly less extent (Figure 6).  18 
miR-26a promotes apoptosis in CLL cells. Given the significant anti-leukemic effect of miR-26a, we 19 
investigated the effect of miR-26a on leukemic splenocytes after 3 weeks of in vivo treatment.  20 
The activation of apoptosis was clearly detectable by analysis of poly(ADP-ribose) polymerase 21 
(PARP) and caspase-7: the appearance of the 85-kD fragment (cleaved PARP), together with the 22 
strong increase in cleavage of caspase-7 were seen only in mice treated with CD38-NP-miR-26a, 23 
thus indicating the induction of apoptosis (Figure 7A). 24 
To confirm that the apoptotic effect could be attributable to miR-26a activity, we analyzed the 25 
levels of two of its targets, Mcl1 and cyclin-dependent kinase 6 (Cdk6). Treatment with CD38-NP-26 
miR-26a induced their downregulation, thus confirming the molecular activity of the delivered 27 
miR-26a (Figure 7B).   28 
 29 
Discussion 30 
The aim of this study was to demonstrate that miRNA-based therapies may have a place in the 31 
treatment of CLL, a human leukemia that is still incurable despite recent multiple successes. Our 32 
approach was based on evidence related to aberrant expressions of miRNA in CLL and on 33 
numerous observations (19, 23, 25, 27, 33).  34 
To address the working hypothesis, we adopted the Eμ-TCL1 mouse model, which develops a 35 
leukemia that is highly similar to an aggressive form of human CLL (15, 16). Using this model, we 36 
previously reported the anti-leukemic activity of miR-181b mimics (28). Here, we assayed miR-15a, 37 
miR-16-1, miR-26a, miR-125a, miR-130a, miR-34a, ant-miR-130a, anti-miR-21, and anti-miR-155. 38 
Among these, miR-26a, miR-130a, and anti-miR-155 induced apoptosis in leukemic cells both in 39 
vitro and in vivo in short-term assays. On the basis of these results, we tested the ability of miR-40 
26a, miR-130a, and anti-miR-155 to counteract the in vivo accumulation/expansion of leukemic 41 
cells of the Eμ-TCL1 mouse model. 42 
miR-155 is a well-known oncomiR (34-39).  In human CLL, a high level of miR-155 was associated 43 
with various adverse prognostic factors (27, 40-43). Overexpression of miR-155 in transgenic mice 44 
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was shown to induce polyclonal B-cell expansion (34). The use of anti-miR-155 molecules has been 1 
reported to significantly decrease in vivo tumor growth of BCWM1 cells derived from a patient 2 
with Waldenstrom macroglobulinemia (44). The role of miR-130a in tumorigenesis is, on the other 3 
hand, controversial. Various reports have indicated either tumor-suppressive (45-51) or oncogenic 4 
(52-56) activity, depending on the experimental settings. In human CLL, miR-130a was shown to 5 
repress a survival autophagic pathway by targeting ATG2B and DICER1 (57). No animal models are 6 
available to examine the physiological or pathological function of miR-130a. Similarly, contrasting 7 
results of dysregulated miR-26a have been reported in different tumor types (58-60). For example, 8 
it was shown that miR-26a could facilitate glioblastoma formation in vivo (58, 61), but it was also 9 
shown that low miR-26a expression conferred a shorter overall survival in liver cancer patients 10 
(62) and that its delivery through an adeno-associated viral vector could achieve a therapeutic 11 
effect on a MYC-induced liver cancer mouse model (59). In human CLL, a tumor suppressive 12 
function of miR-26a was supported by evidence that its low expression was associated with a 13 
shortened time from diagnosis to first treatment (27), a clinical feature associated with poor 14 
prognosis.  15 
Despite the limited evidence linking miR-26a to CLL pathogenesis, this miRNA exhibited the 16 
strongest activity against the accumulation/expansion of leukemic cells by enhancing apoptosis. 17 
Several studies have previously documented that miR-26a is able to target and down-modulate 18 
several protein-coding gene targets, including CDK6, cyclins D2/E2, and Mcl-1, in different tumor 19 
cells (59, 63-65). Here, we found that a strong apoptotic effect was detectable in the spleen of 20 
treated mice and proof of miR-26a activity was confirmed by the downregulation of two of its 21 
known targets, Mcl1 and Cdk6. The concomitant downregulation of the anti-apoptotic Mcl1 and 22 
the cell cycle-promoting Cdk6 proteins suggests not only that miR-26a can promote apoptosis, but 23 
that it can also inhibit CLL cell proliferation.  24 
A second important result of this study was the development of nanoparticles conjugated with 25 
anti-CD38 antibodies that could efficiently deliver miRNA or AMOs into CD38+ cells, which 26 
typically characterize the most aggressive forms of CLL (29) and other hematological diseases such 27 
as myeloma.  In fact, efficient, specific, and safe delivery of miRNA mimics or AMOs is a major 28 
challenge in miRNA-based therapeutic applications (66, 67).  29 
Currently, methods for miRNA systemic delivery are mainly designed to target the liver (68, 69) 30 
and they may use either viral (59, 70, 71) or non-viral systems (72-76). Significant therapeutic 31 
effects in murine liver cancer models have been described (59, 70, 77). More difficult, however, is 32 
the systemic delivery of miRNA mimics to other organs or tissues. Regarding hematopoietic cells, 33 
in vivo delivery of antagomiR-126 was achieved in acute myeloid leukemia subpopulations by 34 
using lipopolyplex nanoparticles conjugated with transferrin or antibody (anti-CD45.2) (72). The 35 
chemical and physical characteristics of this formulation were shown to bypass hepatic uptake and 36 
ultimately achieve better delivery to hematopoietic organs (32). An analogous system based on 37 
stable nucleic acid lipid vesicles conjugated with transferrin was developed to target multiple 38 
myeloma cells expressing transferrin receptors (78, 79). 39 
To develop a method for in vivo delivery to CLL cells, here we produced lipid nanoparticles, based 40 
on the formulation by Huang et al (32), conjugated with an anti-CD38 antibody, whose antigen is 41 
present on the surface of leukemic cells of Eμ-TCL1 mouse model.  Delivery to leukemic cells was 42 
superior to that of either non-conjugated nanoparticles or JetPEI, the nanosystem that we used in 43 
our previous report (28). The presence of the anti-CD38 antibody conferred specificity of action 44 
and also led to internalization of the nanoparticle complex in targeted leukemic spleen cells. The 45 
internalization was previously shown by using a panel of rat and mouse-anti CD38 mAbs (31). The 46 
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results indicated that the adopted methodology is efficient in transferring a cargo of different 1 
miRNAs to leukemic cells. This competence was maintained in vivo. Spleen and liver were the most 2 
efficiently targeted organs by CD38-NPs. A small increase of miR-181b was also detectable in other 3 
organs, especially when non-conjugated nanoparticles were used. Since diseased mice are 4 
characterized by spleno- and hepatomegaly, these results strongly suggested that the CD38-NPs 5 
could increase delivery efficiency to these organs because they accumulate CD38+ CLL cells.  The 6 
characteristics of CD38 targeting in terms of safety were recently confirmed in vivo in mAb-7 
mediated therapy of human myeloma (80).   8 
The main result of this study is that miR-26 exhibits a clear apoptotic effect on leukemic cells and a 9 
significant reduction in leukemic cell expansion, suggesting its consideration for future CLL 10 
therapy, possibly in combination with presently used therapeutic approaches. Moreover, we 11 
provide a novel delivery method, which improves the efficiency and specificity of miRNA delivery 12 
into CD38+ CLL cells. In humans, this approach could help target not only CLL cells in lymphatic 13 
organs, but also other CD38+ B-cell malignancies, including various types of lymphoma, plasma 14 
cell-derived neoplasms, and acute myeloid leukemia of the t(6;9) subtype (81-86). 15 
 16 
Materials and Methods  17 
Cell cultures and transfections. Mouse splenocytes were freshly isolated from diseased mice by 18 
using the procedure described by Bresin et al.(28). Transient transfections were performed with 19 
100 nM pre-miR (Ambion) or single-stranded anti-miRNA (IDT) or scrambled negative controls 20 
complexed with lipidic nanoparticles (NPs or CD38-NPs). Cells were harvested 48 hours after 21 
transfection to evaluate apoptosis and miR expression. 22 
Mice and syngeneic transplantation. The TCL1-tg mouse model used for these experiments has 23 
been previously described (15). Breeding pairs were provided to our group as a generous gift from 24 
C. M. Croce (Ohio State University). FVB WT mice were obtained from Charles River Laboratories. 25 
Mice had ad libitum access to water and a pellet diet. The animal room was maintained at 23°C on 26 
a 12-h light/12-h dark cycle. At the age of 6 weeks, the WT FVB female mice were transplanted by 27 
IP injection of 5x105 lymphocytes isolated from the spleen of an adult TCL1-tg mouse with 28 
established leukemia. The engraftment of leukemic cells and the progression of disease were 29 
monitored over time by the expression of B220/CD5 using flow cytometry analysis (FACS) or 30 
absolute quantification of the human TCL1 transgene by digital PCR of peripheral blood DNA. In 31 
order to comply with the 2010/63/EU directive of the European Parliament and Council, enforced 32 
by the Italian law, which requires that the number of experimental animals be minimized, for long 33 
term experiments, G*Power (http://www.gpower.hhu.de/) was used to define sample size. For 34 
short term experiments, the smallest number of mice sufficient to perform statistical analyses was 35 
used. All animals were randomly assigned to different treatment groups at the start of the studies. 36 
The protocol for animal experimentation was approved by the Italian Ministry of Health (approval 37 
n. 40-2014 PR released on November 6, 2014). 38 
Anti-CD38 monoclonal antibody. The anti-CD38 antibody is a rat monoclonal antibody (mAb) 39 
specific for mouse CD38 antigen. It was produced in the laboratory of one of the authors (FM, 40 
University of Turin). The NIMR-5 clone was expanded in vitro in Iscove’s Modified Dulbecco’s 41 
Medium and purified by high pressure liquid chromatography. The purified IgG was then sterilized 42 
by 0.22-μm filtration (Millipore Polyethersulfone Millex-GP Syringe Filter Unit, radiosterilized) and 43 
detoxified by Detoxi-Gel Endotoxin Removing Gel (Thermo Scientific) (87). Specificity was 44 
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confirmed by reacting the purified mAb with the murine X63.Ag8 myeloma cell line and analyzing 1 
binding by indirect immunofluorescence (87). 2 
Preparation of nanoparticles. The lipid components of the nanoparticles were 1,2-dioleoyl-sn-3 
glycero-3-phosphoethanolamine (DOPE), 1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol 4 
(MW ~2000; DMG-PEG; Avanti Polar Lipids, Alabaster, AL), and linoleic acid (Sigma-Aldrich, St. 5 
Louis, MO). The molar ratio of DOPE:linoleic acid:DMG-PEG was 50:48:2. The preparation of empty 6 
nanoparticles was performed as previously described (32). The anti-CD38 antibody was conjugated 7 
with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide (polyethylene glycol)-2000] 8 
(DSPE-PEG2000 maleimide) according to the method described in a previous study (72) and was 9 
then post-inserted into the surface of lipopolyplex nanoparticles to form the CD38-NP-miRs.  10 
In vivo treatment with mimics or AMOs. The synthetic mimics and anti-miRNAs for in vivo delivery 11 
were purchased from Axolab (Germany).  For short-term experiments, the FVB mice (at least 3 12 
mice in each group)  were randomly enrolled for treatment when the disease reached 30-50% of 13 
TCL1-positive cells in peripheral blood, and they were treated once with 100 µg of specific single-14 
strand mimics/anti-miRNA and sacrificed after 48 hours. For long-term experiments, the mice (at 15 
least 6 mice in each group) were randomly enrolled for treatment when the disease reached 15-16 
30% of TCL1-positive cells in peripheral blood, and they were treated with  100 µg of the specified 17 
molecules 3 times a week for 3 weeks. For long-term treatments, the levels of disease were 18 
measured by FACS and droplet digital PCR (ddPCR) analysis the day before the start of treatment 19 
and 48 hours after it ended.  20 
Flow cytometry.  Blood samples (20 μL) were placed in a tube containing 0.5 M EDTA as an 21 
anticoagulant. Erythrocytes were lysed by treatment with ammonium chloride (0.8%) and EDTA 22 
(0.1 mM) (Sigma). Cells were incubated with specific antibodies for 10 min in ice, washed, and 23 
analyzed by flow cytometry in a FACSCalibur flow cytometer (Becton Dickinson, San Jose, 24 
California, USA) by using FlowJo software (TreeStar, Ashland, OR). Data for 5x104 cells within the 25 
lymphocyte light-scatter gate were collected. In these assays, color compensation was performed 26 
before cell acquisition by using the MACS Comp Bead Kit, anti-rat Igκ (Miltenyi Biotec, Gladbach, 27 
Germany). During analysis, gates were set by using a Fluorescence Minus One control strategy. 28 
Leukemic cells were identified as B220+/CD5dim cells, normal B lymphocytes as B220+/CD5- cells,  29 
and T lymphocytes as B220-/CD5+ cells. The following antibodies were used: FITC rat anti-mouse 30 
CD5 (Cat. 553020, BD Pharmingen) and PeCy5 rat anti-mouse CD45R/B220 (Cat. 553091, BD 31 
Pharmingen). CD38 expression on the surface of leukemic splenocytes was detected by triple 32 
staining using a PE rat anti-mouse CD38 antibody (Cat. 130-103-008, Miltenyi Biotec) together 33 
with the FITC rat anti-mouse CD5 and the PeCy5 rat anti-mouse CD45R/B220 antibody indicated 34 
above.   35 
Analysis of apoptosis. The apoptotic effect of mimic or anti-miR molecules on murine splenocytes 36 
treated in vitro or in vivo was assessed by the Muse™ Annexin V and Dead Cell Assay kit (Cat. 37 
MCH100105, Merck) according to manufacturer’s protocol. To count viable cells, we used the 38 
Muse Count & Viability Assay kit (Cat. MHC100102, Merck). 39 
RNA and DNA extraction. Total RNA and DNA were isolated from cells or tissues by using the 40 
Maxwell Rapid Sample Concentrator (RSC) Instrument (Promega) with the Maxwell RSC miRNA 41 
Tissue Kit and the Maxwell RSC Blood DNA Kit. 42 
Reverse transcription and ddPCR.  The ddPCR method was used to measure the expression level 43 
of miRNAs. The reverse transcription reaction was performed on 5 ng of total RNA by using the 44 
TaqMan miRNA Reverse Transcription assay. After appropriate dilution, 1 μL of the cDNA was used 45 
10 
 
for amplification in a 20-μL reaction volume containing ddPCR Supermix for Probes (Bio-Rad) and 1 
the TaqMan miRNA PCR probe set. Droplets generation, cycling conditions for TaqMan assays and 2 
the counting of positive droplets were performed according to procedures described by Miotto et 3 
al. (88).  To normalize the relative abundance of miRNAs, we used the Taqman Assays for RNAs U6 4 
or SNO412 (Applied Biosystems). 5 
Monitoring leukemic cells by ddPCR.   A ddPCR approach was used to measure the human TCL1 6 
transgene in DNA extracted from peripheral blood cells of FVB transplanted mice. We used 7 
primers/probes specific for the human TCL1 transgene (forward 5’-CTCTGGCTCTTGCTTCTTAG-3’; 8 
reverse 5’-CACCCGTAACTGTAACCTATC-3’; probe--/56-FAM/TCGTGTATT/Zen/TGGACGAGAAGCA 9 
GCA/3IABkFQ/) and primers/probes specific for the mouse Gapdh gene as an endogenous 10 
reference (forward 5’-GGTGTGAACCACGAGAAATA-3’; reverse 5’-CTCATGGCAGGGTAAGATAAG-3’; 11 
probe--/5HEX/ACAAC TTTG/Zen/GCATTGTGGAAGGGC/3IABkFQ/). The probes for human TCL1 and 12 
mouse Gapdh were conjugated with FAM and HEX, respectively. The ddPCR assay was performed 13 
on 10 ng of genomic DNA, using the same procedures as described above.  14 
Western blot analysis. Splenocytes of treated and control mice were suspended in 15 
radioimmunoprecipitation assay (RIPA) buffer (Sigma-Aldrich), supplemented with protease and 16 
phosphatase inhibitors (Sigma-Aldrich), according to the manufacturer's protocol. Protein 17 
concentrations were measured with the Bradford assay (Bio-Rad). Equal amounts (30 µg) of 18 
protein extracts from all samples were applied to SDS-PAGE electrophoresis and then transferred 19 
to a PVDF membrane (Bio-Rad). The membrane was incubated with  primary antibodies as follows: 20 
anti-CDK6 (rabbit, Cat. sc177, Santa  Cruz), anti-Mcl-1 (Rabbit, Cat.5453 Cell Signalling) , anti-PARP 21 
(rabbit, Cat. 9542, Cell Signalling) , anti-caspase-7 (rabbit, Cat. 9492, Cell Signaling) 1:1000. β-22 
Tubulin H235 (rabbit, Cat. sc9104, Santa Cruz), , was used as a normalized control. The membrane 23 
was incubated with anti-rabbit IgG, HRP-linked antibody  (Cat. 7074, Cell Signaling). For signal 24 
detection, ClarityTM Western ECL Substrate (Cat. 170-5060, Bio-Rad) was used according to the 25 
manufacturer's instructions. Digital images were acquired with Chemidoc (BioRad). Signals were 26 
quantified by ImageJ software and protein expression levels normalized according to β-tubulin 27 
expression. 28 
Statistical analyses. Reported data are expressed as mean ± SD; the calculated t-test or t-test with 29 
Welch's correction when required were considered statistically significant at p-value < 0.05. 30 
Variances between groups were evaluated by the F-test. Graphpad Prism 6.0 software was used 31 
for data analysis. No samples or animals were excluded from the analyses. None of the 32 
investigators were blinded to group allocations. 33 
Conflict of Interest: The authors declare no competing financial interests. 34 
Acknowledgements 35 
This work was supported by funds from the Italian Association for Cancer Research (AIRC Special 36 
program 5xmille n.9980) and the University of Ferrara to MN, from the US National Cancer 37 
Institute grant CA19-7706 to CMC, from FIRB Programme of the Ministry of University and 38 
Research (Rome, Italy), Fondazione Cassa di Risparmio di Torino and Fondazione Ricerca Molinette 39 
Torino to FM.   40 
Supplementary Information accompanies the paper on the Oncogene website 41 
(http://www.nature.com/onc)42 
11 
 
Reference 1 
1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. The New England journal of 2 
medicine. 2005;352(8):804-15. 3 
2. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic 4 
lymphocytic leukaemia. Nature reviews Cancer. 2010;10(1):37-50. 5 
3. Chiorazzi N, Hatzi K, Albesiano E. B-cell chronic lymphocytic leukemia, a clonal disease of B 6 
lymphocytes with receptors that vary in specificity for (auto)antigens. Annals of the New York Academy of 7 
Sciences. 2005;1062:1-12. 8 
4. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, et al. Comprehensive 9 
assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic 10 
leukemia: results from the US Intergroup Phase III Trial E2997. Journal of clinical oncology : official journal 11 
of the American Society of Clinical Oncology. 2007;25(7):799-804. 12 
5. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic 13 
classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 14 
1981;48(1):198-206. 15 
6. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 16 
expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-7. 17 
7. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression 18 
identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical 19 
outcome, and distinct gene expression profile. Blood. 2003;101(12):4944-51. 20 
8. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and 21 
survival in chronic lymphocytic leukemia. The New England journal of medicine. 2000;343(26):1910-6. 22 
9. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL 23 
and their evolution in progression and relapse. Nature. 2015;526(7574):525-30. 24 
10. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, et al. Mutations of the SF3B1 25 
splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-26 
refractoriness. Blood. 2011;118(26):6904-8. 27 
11. Cuneo A, Cavazzini F, Ciccone M, Daghia G, Sofritti O, Saccenti E, et al. Modern treatment in chronic 28 
lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer medicine. 29 
2014;3(3):555-64. 30 
12. Simonetti G, Bertilaccio MT, Ghia P, Klein U. Mouse models in the study of chronic lymphocytic 31 
leukemia pathogenesis and therapy. Blood. 2014;124(7):1010-9. 32 
13. Bresin A, D'Abundo L, Narducci MG, Fiorenza MT, Croce CM, Negrini M, et al. TCL1 transgenic 33 
mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic 34 
lymphocytic leukemia. Cell death & disease. 2016;7:e2071. 35 
14. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic 36 
leukemia modeled in mouse by targeted TCL1 expression. Proceedings of the National Academy of Sciences 37 
of the United States of America. 2002;99(10):6955-60. 38 
15. Efanov A, Zanesi N, Nazaryan N, Santanam U, Palamarchuk A, Croce CM, et al. CD5+CD23+ leukemic 39 
cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation. 40 
Leukemia. 2010;24(5):970-5. 41 
16. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, et al. B cell receptors in TCL1 42 
transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. 43 
Proceedings of the National Academy of Sciences of the United States of America. 2006;103(31):11713-8. 44 
17. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of 45 
the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic 46 
leukemia. Blood. 2006;108(4):1334-8. 47 
18. Negrini M, Ferracin M, Sabbioni S, Croce CM. MicroRNAs in human cancer: from research to 48 
therapy. Journal of cell science. 2007;120(Pt 11):1833-40. 49 
12 
 
19. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-1 
regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of 2 
the National Academy of Sciences of the United States of America. 2002;99(24):15524-9. 3 
20. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/miR-15a/16-1 cluster controls B 4 
cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer cell. 2010;17(1):28-40. 5 
21. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce 6 
apoptosis by targeting BCL2. Proceedings of the National Academy of Sciences of the United States of 7 
America. 2005;102(39):13944-9. 8 
22. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with 9 
Venetoclax in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine. 10 
2016;374(4):311-22. 11 
23. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature 12 
associated with prognosis and progression in chronic lymphocytic leukemia. The New England journal of 13 
medicine. 2005;353(17):1793-801. 14 
24. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, et al. Association of a 15 
microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. 16 
JAMA : the journal of the American Medical Association. 2011;305(1):59-67. 17 
25. Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, et al. miR-181b is a biomarker of 18 
disease progression in chronic lymphocytic leukemia. Blood. 2011;118(11):3072-9. 19 
26. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour 20 
suppressor network. Nature. 2007;447(7148):1130-4. 21 
27. Negrini M, Cutrona G, Bassi C, Fabris S, Zagatti B, Colombo M, et al. microRNAome expression in 22 
chronic lymphocytic leukemia: comparison with normal B cell subsets and correlations with prognostic and 23 
clinical parameters. Clinical cancer research : an official journal of the American Association for Cancer 24 
Research. 2014;20(15):4141-53. 25 
28. Bresin A, Callegari E, D'Abundo L, Cattani C, Bassi C, Zagatti B, et al. miR-181b as a therapeutic agent 26 
for chronic lymphocytic leukemia in the Emicro-TCL1 mouse model. Oncotarget. 2015;6(23):19807-18. 27 
29. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic 28 
leukemia: a decade later. Blood. 2011;118(13):3470-8. 29 
30. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of 30 
the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiological reviews. 31 
2008;88(3):841-86. 32 
31. Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, et al. Anti-CD38 antibody 33 
therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med. 34 
2013;19:99-108. 35 
32. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, et al. Targeted delivery of 36 
microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in 37 
acute myeloid leukemia. Clinical cancer research : an official journal of the American Association for Cancer 38 
Research. 2013;19(9):2355-67. 39 
33. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the 40 
pathogenesis of chronic lymphocytic leukemia. Best practice & research Clinical haematology. 41 
2007;20(3):425-37. 42 
34. Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, et al. Pre-B cell proliferation and 43 
lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proceedings of the 44 
National Academy of Sciences of the United States of America. 2006;103(18):7024-9. 45 
35. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, et al. Sustained expression of 46 
microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. The Journal of 47 
experimental medicine. 2008;205(3):585-94. 48 
36. Tagawa H, Ikeda S, Sawada K. Role of microRNA in the pathogenesis of malignant lymphoma. 49 
Cancer science. 2013;104(7):801-9. 50 
13 
 
37. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. 1 
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer 2 
Research, cosponsored by the American Society of Preventive Oncology. 2012;21(8):1236-43. 3 
38. Zanesi N, Pekarsky Y, Trapasso F, Calin G, Croce CM. MicroRNAs in mouse models of lymphoid 4 
malignancies. Journal of nucleic acids investigation. 2010;1(1):36-40. 5 
39. Garzon R, Croce CM. MicroRNAs in normal and malignant hematopoiesis. Current opinion in 6 
hematology. 2008;15(4):352-8. 7 
40. Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, et al. MicroRNA-155 influences B-cell receptor 8 
signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546-9 
54. 10 
41. Visone R, Rassenti LZ, Veronese A, Taccioli C, Costinean S, Aguda BD, et al. Karyotype-specific 11 
microRNA signature in chronic lymphocytic leukemia. Blood. 2009;114(18):3872-9. 12 
42. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, et al. microRNA fingerprinting 13 
of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 14 
2010;116(6):945-52. 15 
43. Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, et al. MYB transcriptionally regulates 16 
the miR-155 host gene in chronic lymphocytic leukemia. Blood. 2011;117(14):3816-25. 17 
44. Zhang Y, Roccaro AM, Rombaoa C, Flores L, Obad S, Fernandes SM, et al. LNA-mediated anti-miR-18 
155 silencing in low-grade B-cell lymphomas. Blood. 2012;120(8):1678-86. 19 
45. Zhu X, Zhao H, Lin Z, Zhang G. Functional studies of miR-130a on the inhibitory pathways of 20 
apoptosis in patients with chronic myeloid leukemia. Cancer gene therapy. 2015;22(12):573-80. 21 
46. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, et al. miR-130a targets MET and 22 
induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 2012;31(5):634-42. 23 
47. Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G, et al. MicroRNA-130a inhibits cell proliferation, 24 
invasion and migration in human breast cancer by targeting the RAB5A. International journal of clinical and 25 
experimental pathology. 2015;8(1):384-93. 26 
48. Li Y, Challagundla KB, Sun XX, Zhang Q, Dai MS. MicroRNA-130a associates with ribosomal protein 27 
L11 to suppress c-Myc expression in response to UV irradiation. Oncotarget. 2015;6(2):1101-14. 28 
49. Fujita Y, Kojima T, Kawakami K, Mizutani K, Kato T, Deguchi T, et al. miR-130a activates apoptotic 29 
signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. The Prostate. 30 
2015;75(14):1568-78. 31 
50. Li B, Huang P, Qiu J, Liao Y, Hong J, Yuan Y. MicroRNA-130a is down-regulated in hepatocellular 32 
carcinoma and associates with poor prognosis. Med Oncol. 2014;31(10):230. 33 
51. Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, et al. MiR-130a, miR-203 and miR-34 
205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 35 
2013;32(3):277-85. 36 
52. Shen S, Guo X, Yan H, Lu Y, Ji X, Li L, et al. A miR-130a-YAP positive feedback loop promotes organ 37 
size and tumorigenesis. Cell research. 2015;25(9):997-1012. 38 
53. Lee SH, Jung YD, Choi YS, Lee YM. Targeting of RUNX3 by miR-130a and miR-495 cooperatively 39 
increases cell proliferation and tumor angiogenesis in gastric cancer cells. Oncotarget. 2015;6(32):33269-40 
78. 41 
54. Chen J, Yan D, Wu W, Zhu J, Ye W, Shu Q. MicroRNA-130a promotes the metastasis and epithelial-42 
mesenchymal transition of osteosarcoma by targeting PTEN. Oncology reports. 2016;35(6):3285-92. 43 
55. Jiang H, Yu WW, Wang LL, Peng Y. miR-130a acts as a potential diagnostic biomarker and promotes 44 
gastric cancer migration, invasion and proliferation by targeting RUNX3. Oncology reports. 45 
2015;34(3):1153-61. 46 
56. Liu L, Nie J, Chen L, Dong G, Du X, Wu X, et al. The oncogenic role of microRNA-130a/301a/454 in 47 
human colorectal cancer via targeting Smad4 expression. PloS one. 2013;8(2):e55532. 48 
57. Kovaleva V, Mora R, Park YJ, Plass C, Chiramel AI, Bartenschlager R, et al. miRNA-130a targets 49 
ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. Cancer 50 
research. 2012;72(7):1763-72. 51 
14 
 
58. Kim H, Huang W, Jiang X, Pennicooke B, Park PJ, Johnson MD. Integrative genome analysis reveals 1 
an oncomir/oncogene cluster regulating glioblastoma survivorship. Proceedings of the National Academy of 2 
Sciences of the United States of America. 2010;107(5):2183-8. 3 
59. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic 4 
microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009;137(6):1005-17. 5 
60. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 6 
expression by repression of its negative regulator miR-26a. Blood. 2008;112(10):4202-12. 7 
61. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, et al. The PTEN-regulating 8 
microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes & 9 
development. 2009;23(11):1327-37. 10 
62. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, et al. MicroRNA expression, survival, and response 11 
to interferon in liver cancer. The New England journal of medicine. 2009;361(15):1437-47. 12 
63. Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, et al. MicroRNA-26a suppresses tumor growth and 13 
metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology. 14 
2013;58(1):158-70. 15 
64. Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, et al. MicroRNA-26a/b and their host genes cooperate to 16 
inhibit the G1/S transition by activating the pRb protein. Nucleic acids research. 2012;40(10):4615-25. 17 
65. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, et al. MiR-26a inhibits proliferation and migration of breast 18 
cancer through repression of MCL-1. PloS one. 2013;8(6):e65138. 19 
66. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. Journal of controlled release : 20 
official journal of the Controlled Release Society. 2013;172(3):962-74. 21 
67. Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. 22 
Advanced drug delivery reviews. 2014;81:128-41. 23 
68. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs 24 
in vivo with 'antagomirs'. Nature. 2005;438(7068):685-9. 25 
69. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing 26 
in non-human primates. Nature. 2008;452(7189):896-9. 27 
70. Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F, et al. Anti-tumor activity of a 28 
miR-199-dependent oncolytic adenovirus. PloS one. 2013;8(9):e73964. 29 
71. Amendola M, Passerini L, Pucci F, Gentner B, Bacchetta R, Naldini L. Regulated and multiple miRNA 30 
and siRNA delivery into primary cells by a lentiviral platform. Molecular therapy : the journal of the 31 
American Society of Gene Therapy. 2009;17(6):1039-52. 32 
72. Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, et al. Targeting leukemia 33 
stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia. 34 
2015;29(11):2143-53. 35 
73. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nature 36 
reviews Drug discovery. 2014;13(8):622-38. 37 
74. Masotti A, Miller MR, Celluzzi A, Rose L, Micciulla F, Hadoke PW, et al. Regulation of angiogenesis 38 
through the efficient delivery of microRNAs into endothelial cells using polyamine-coated carbon 39 
nanotubes. Nanomedicine : nanotechnology, biology, and medicine. 2016;12(6):1511-22. 40 
75. Taccioli C, Garofalo M, Chen H, Jiang Y, Tagliazucchi GM, Di Leva G, et al. Repression of Esophageal 41 
Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo. Journal of the National Cancer 42 
Institute. 2015;107(11). 43 
76. Ghosh R, Singh LC, Shohet JM, Gunaratne PH. A gold nanoparticle platform for the delivery of 44 
functional microRNAs into cancer cells. Biomaterials. 2013;34(3):807-16. 45 
77. Jia XQ, Cheng HQ, Qian X, Bian CX, Shi ZM, Zhang JP, et al. Lentivirus-mediated overexpression of 46 
microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma. Cell biochemistry and 47 
biophysics. 2012;62(1):237-44. 48 
78. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gulla A, Foresta U, et al. In vivo activity of 49 
miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PloS 50 
one. 2014;9(2):e90005. 51 
15 
 
79. Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gulla A, et al. Transferrin-1 
conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. 2 
BioMed research international. 2014;2014:217365. 3 
80. van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, et al. Clinical efficacy and 4 
management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 5 
2016;127(6):681-95. 6 
81. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, et al. CD38 expression as an important 7 
prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98(1):181-6. 8 
82. Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, et al. The enzymatic activities of 9 
CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia. 2015;29(2):356-10 
68. 11 
83. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the 12 
molecular basis of treatment in the genomic era. Blood. 2011;117(1):26-38. 13 
84. Bende RJ, Smit LA, Bossenbroek JG, Aarts WM, Spaargaren M, de Leval L, et al. Primary follicular 14 
lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an 15 
origin from local antigen-experienced B cells. The American journal of pathology. 2003;162(1):105-13. 16 
85. Colomo L, Loong F, Rives S, Pittaluga S, Martinez A, Lopez-Guillermo A, et al. Diffuse large B-cell 17 
lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. The 18 
American journal of surgical pathology. 2004;28(6):736-47. 19 
86. Ansari MQ, Dawson DB, Nador R, Rutherford C, Schneider NR, Latimer MJ, et al. Primary body 20 
cavity-based AIDS-related lymphomas. American journal of clinical pathology. 1996;105(2):221-9. 21 
87. Horenstein AL, Durelli I, Malavasi F. Purification of clinical-grade monoclonal antibodies by 22 
chromatographic methods. Methods Mol Biol. 2005;308:191-208. 23 
88. Miotto E, Saccenti E, Lupini L, Callegari E, Negrini M, Ferracin M. Quantification of circulating 24 
miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancer 25 
epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, 26 
cosponsored by the American Society of Preventive Oncology. 2014;23(12):2638-42. 27 
  28 
16 
 
FIGURES LEGENDS 1 
 2 
Figure 1. In the Eμ-TCL1FL TG mouse, the leukemic population (B220+/CD5dim) is CD38+. Cells 3 
were isolated from the spleen of an adult Eμ-TCL1FL transgenic mouse (upper panels) or a 4 
transplanted FVB-TCL1 mouse (lower panels). The left panels show the lymphocyte population, the 5 
middle panels the B220+/Cd5dim leukemic population. The right panels show the CD38+ 6 
lymphocytes within the B220+/CD5dim population: more than 98% of the cells are positive. 7 
 8 
Figure 2. Bio-distribution of miR-181 after the use of CD38-NPs as an in vivo delivery agent.  (A) 9 
Bio-distribution 24 hours after intraperitoneal injection of miR-181b mimics (100 µg) delivered 10 
into a transplanted FVB-TCL1 mouse with a high level of disease by the use of CD38-NP, regular 11 
nanoparticles (NPs), or Jet-PEI. (B) Highlights of splenocytes and liver.  Treatment with CD38-NPs 12 
induces the most significant increase in the miR-181b level in splenocytes compared with other 13 
tissues or methods of delivery ( ** p < 0.001,  * p < 0.05, respectively), likely reflecting the high 14 
number of CD38+ leukemic lymphocytes present in this organ. The results are normalized to 15 
SNO412 expression. 16 
 17 
Figure 3. Pro-apoptotic activity of different miRNA mimics/AMOs in leukemic splenocytes in 18 
vitro. (A) The apoptotic activity of miRNAs/anti-miRNAs in leukemic splenocytes was evaluated by 19 
the Muse Cell Analyzer using the Muse Annexin V & Dead Cell Assay 48 hours after transfection. 20 
Statistical assessment of each miRNA effect is referred to the Scramble control.  *= p < 0.05 (t-21 
test). (B) The level of each miRNA after transfection was assessed by ddPCR at the time when 22 
apoptosis measured.  miRNA levels were normalized on SNO412 and non-transfected cells (UNT). 23 
 24 
Figure 4. CD38-NPs mediate an in vivo more effective functional outcome than non-conjugated 25 
NPs. Forty-eight hours after a single injection of miR-26a mimics (100 ug) with CD38-NPs or non-26 
conjugated NPs, mice with established leukemia were sacrificed, splenocytes were isolated and 27 
analyzed for RNA and protein expression. CD38-NP-miRNA26a produced a higher level of miR-26a 28 
than NP-miR26a. The results are shown as relative expression of miR-26a normalized to SNO412 29 
expression, as measured by ddPCR. As a result, the treatment with CD38-NPs could mediate more 30 
effective functional outcomes as revealed by a clearer apoptotic effect (cleavage of PARP) and a 31 
stronger down regulation of a miR-26a target (CDK6). 32 
 33 
Figure 5. Apoptotic activity of miRNA/anti-miRNA molecules after a single in vivo treatment of 34 
mice with established leukemia. Mice with established leukemia were sacrificed 48 hours after a 35 
single treatment with miRNA/anti-miRNA molecules. Splenocytes were isolated to evaluate 36 
apoptosis.  (A) Using an Annexin V assay, we observed a significant  increase in the percentage of 37 
apoptotic cells 48 hours after treatment with CD38-NP-miR-26a (p = 0.013), CD38-NP-miR-130a (p 38 
=  0.03), or CD38-NP-anti-miR-155 (p = 0.002). (B) At the same time, the relative expression of miR-39 
16, miR-26a, miR-155, miR-130a, miR-34a, and miR-21 was measured in splenocytes by using 40 
ddPCR. The results are shown as the relative expression level, normalized to SNO412 expression. 41 
 42 
Figure 6. miR-26a exhibits the strongest activity against Eμ-TCL1FL leukemic cells.  Percentages of 43 
circulating leukemic cells were measured just before starting treatments and 48 hours after their 44 
completion.  The differences between these points were acquired and plotted for each mouse 45 
enrolled in the study. miR-26a exhibited the strongest effect on expansion of leukemic burden, as 46 
shown in the graph and by the p-values in the associated table. P-values < 0.05 are highlighted by 47 
a grey background. N = number of mice, SD = standard deviation.  48 
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Figure 7. Modulation of pro-apoptotic proteins and direct targets of miR-26a in vivo. Forty-eight 2 
hours after the end of long-term treatments, mice were sacrificed and the spleen collected. 3 
Proteins were extracted from splenocytes of CD38-NP-miR-26a-treated and control mice for 4 
Western blot analysis. (A) Cleaved PARP and cleaved caspase-7 are evidence of apoptosis and 5 
were clearly visible in the samples treated with miR-26a, but not in the controls. (B) The direct 6 
molecular activity of miR-26a was demonstrated by showing that two of its known targets, Mcl1 7 
and Cdk6, were down-modulated in the samples treated with miR-26a, but not in the control. 8 
 9 
 10 
 11 







